AvantorAVTR
AVTR
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.51% more ownership
Funds ownership: 99.76% [Q3] → 100.27% (+0.51%) [Q4]
7% less funds holding
Funds holding: 503 [Q3] → 469 (-34) [Q4]
18% less capital invested
Capital invested by funds: $17.5B [Q3] → $14.4B (-$3.13B) [Q4]
20% less repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 202
23% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 10 (-3) [Q4]
27% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 79
64% less call options, than puts
Call options by funds: $52.6M | Put options by funds: $145M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
33%
upside
Avg. target
$26
48%
upside
High target
$31
79%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Morgan Stanley Tejas Savant 22% 1-year accuracy 4 / 18 met price target | 45%upside $25 | Overweight Maintained | 10 Feb 2025 |
Raymond James Andrew Cooper 14% 1-year accuracy 2 / 14 met price target | 39%upside $24 | Outperform Reiterated | 10 Feb 2025 |
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target | 79%upside $31 | Outperform Maintained | 10 Feb 2025 |
Wells Fargo Brandon Couillard 14% 1-year accuracy 3 / 22 met price target | 45%upside $25 | Overweight Maintained | 10 Feb 2025 |
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target | 33%upside $23 | Overweight Maintained | 10 Feb 2025 |
Financial journalist opinion
Based on 9 articles about AVTR published over the past 30 days
Neutral
PRNewsWire
2 days ago
Avantor® to Present at TD Cowen's 45th Annual Health Care Conference
RADNOR, Pa. , Feb. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will present at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, at 11:50 a.m.
Neutral
Business Wire
2 days ago
Silq Technologies Corp. and NuSil Technology LLC Announce Collaboration Agreement to Drive Broad-based Adoption of Silq's Novel Surface Treatment Technology
SUNNY ISLES BEACH, Fla.--(BUSINESS WIRE)--Silq Technologies Corporation, a privately held advanced materials science company, and NuSil Technology LLC, a subsidiary of Avantor Inc., Radnor, Pa. (NYSE: AVTR), and a leading global supplier of high-quality silicones for long-term medical implants, have entered into an agreement to facilitate the utilization of Silq's zwitterionic surface treatment technology on medical devices manufactured with NuSil silicone products. Zwitterion surface technolog.
Positive
Zacks Investment Research
1 week ago
Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand
Despite AVTR's stability in proprietary chemicals and specialty procurement sales, it reports an overall soft fourth-quarter performance.
Neutral
Seeking Alpha
2 weeks ago
Avantor, Inc. (AVTR) Q4 2024 Earnings Call Transcript
Avantor, Inc. (NYSE:AVTR ) Q4 2024 Earnings Conference Call February 7, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications Michael Stubblefield - President and CEO Brent Jones - EVP and CFO Conference Call Participants Vijay Kumar - Evercore ISI Michael Ryskin - Bank of America Daniel Brennan - TD Cowen Rachel Vatnsdal - JP Morgan Tycho Peterson - Jefferies Luke Sergott - Barclays Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Conor McNamara - RBC Capital Markets Ivy Ma - Goldman Sachs Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Operator Hello everybody and a warm welcome to Avantor's Fourth Quarter 2024 Earnings Call. My name is Emily and I'll be coordinating your call today.
Positive
Zacks Investment Research
2 weeks ago
Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Benzinga
2 weeks ago
Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025
On Friday, Avantor Inc AVTR reported fourth-quarter net sales of $1.69 billion, a decrease of 2% year-over-year, missing the consensus of $1.71 billion.
Positive
Zacks Investment Research
2 weeks ago
Avantor, Inc. (AVTR) Surpasses Q4 Earnings Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.25 per share a year ago.
Neutral
PRNewsWire
2 weeks ago
Avantor® Reports Fourth Quarter and Full Year 2024 Results
Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1% Net income of $500.4 million; Adjusted EBITDA of $307.7 million Diluted GAAP EPS of $0.73; adjusted EPS of $0.27 Operating cash flow of $173.3 million; free cash flow of $222.1 million Full Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2% Net income of $711.5 million; Adjusted EBITDA of $1,198.8 million Diluted GAAP EPS of $1.04; adjusted EPS of $0.99 Operating cash flow of $840.8 million; free cash flow of $768.3 million RADNOR, Pa. , Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its fourth fiscal quarter and year ended December 31, 2024.
Neutral
Business Wire
2 weeks ago
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand availability of its innovative nucleic acid products to customers across Europe, Middle East, and Africa (EMEA). This distribution pa.
Positive
Zacks Investment Research
1 month ago
MD vs. AVTR: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
Charts implemented using Lightweight Charts™